A Comprehensive Update on Recent Developments and Share Structure
Vivos Inc. has been making waves with recent FDA designations, executive agreements, clinic certifications, and updates to their share structure, highlighting a period of dynamic growth and innovation. Vivos Inc. stands at the forefront of medical and veterinary innovation, with recent breakthroughs and expansions setting new industry standards.
Vivos Inc Stock Price Today | OTC RDGL Live Ticker – Investing.com
The recent achievement of (OTCQB: RDGL) Certification marks a significant chapter in the evolving narrative of Vivos Inc., underscoring its unwavering dedication to transparency, regulatory compliance, and the highest echelons of corporate governance.
On the 22nd of March, 2024, CEO Dr. Michael Korenko led the company in affirming its commitment to upholding stringent reporting and operational standards, by securing its registration under Section 12(g) of the Exchange Act.
This critical development not only exemplifies Vivos Inc.’s commitment to meet and exceed rigorous financial reporting standards but also signals its continued promise to furnish stakeholders with lucid and thorough insights into its corporate undertakings and the overall state of its financial health.
OTCQB certification is more than a mere procedural milestone; it’s a testament to Vivos Inc.’s strategic foresight and its proactive stance in nurturing trust and confidence among its investors and partners. For a comprehensive understanding of the implications and details of this certification, click here to delve deeper.
Vivos Inc.’s Strategic Milestones: A Year in Review
Vivos Inc. has marked significant achievements across its operations, underscoring its commitment to innovation in cancer treatment and veterinary care. Discover the specifics of Vivos Inc.’s renewed Executive Employment Agreement with CEO Dr. Michael Korenko, detailing his compensation, tenure, and obligations. Full details here.
A Renewed Leadership Commitment
- Annual Base Salary: The agreement sets Dr. Korenko’s annual salary at $295,500, reflecting his invaluable contribution to the company.
- Stock Options: As part of his compensation, Dr. Korenko is granted 20,000 shares of restricted stock, vesting over two years, tying his success to the company’s prosperity.
- Performance Bonuses: Demonstrating a performance-driven culture, the agreement entitles Dr. Korenko to a potential $10,000 bonus per quarter, subject to the Board’s satisfaction with his performance.
- Additional Benefits: Beyond the financials, the agreement covers customary benefits and reimbursement for reasonable business expenses, underlining the company’s commitment to supporting its CEO.
With this renewal, Vivos, Inc. not only reaffirms its trust in Dr. Korenko’s leadership but also sets a clear path for the company’s future direction. The detailed terms underscore a mutual commitment to growth, performance, and success.
Spotlighting Key Milestones for Vivos Inc.
On December 20, 2023, Vivos Inc. marked a significant milestone as the FDA granted its RadioGel™ Precision Radionuclide Therapy the coveted Breakthrough Device Designation. This recognition underlines the innovative nature and potential impact of RadioGel™ on cancer treatment. RDGL – Vivos Inc. | Disclosure | OTC Markets
FDA’s Recognition: A Testament to Innovation Dr. Mike Korenko, the CEO of Vivos Inc., expressed satisfaction with the FDA’s decision, which followed a comprehensive review of recent data submissions. The company’s Risk Management Report underscored RadioGel™’s intrinsic safety and effectiveness, further validated by animal therapy data.
Pioneering Treatment for Thyroid Cancer Vivos Inc. is collaborating with Mayo Clinic on an initial indication for RadioGel™ targeting solid metastatic tumors in lymph nodes associated with papillary thyroid cancer. This approach serves patients who are not surgical candidates or have declined surgery, offering a new horizon in cancer treatment.
The Breakthrough Devices Program: Facilitating Innovation The FDA’s Breakthrough Devices Program aims to accelerate the development and review of groundbreaking technologies. RadioGel™’s designation promises an expedited path for its Investigational Device Exemption (IDE) submission and subsequent clinical trials, potentially offering patients more effective treatment options sooner.
RadioGel™: A Closer Look at the Technology RadioGel™ utilizes yttrium-90 phosphate microparticles within a proprietary hydrogel, allowing for precise, localized radiation treatment directly inside tumors. This method significantly reduces side effects and risks associated with traditional external-beam radiation, enabling safe, higher-dose treatments for challenging cancers.
IsoPet®: Extending Benefits to Veterinary Medicine Parallel to RadioGel™, Vivos Inc. has successfully applied its technology in veterinary medicine through IsoPet®. This division of the company focuses on treating animal cancers, demonstrating the safety and therapeutic effectiveness of this technology in pets.
Expanding the IsoPet® Network
In a significant expansion of its veterinary services, Vivos Inc. has certified three new clinics to offer its groundbreaking IsoPet® Precision Radionuclide Therapy. This expansion brings new hope to pet parents seeking advanced cancer treatment options for their beloved animals.
The Myhre Equine Clinic, Rochester, New Hampshire
Hopkinton Animal Hospital, Weare, New Hampshire
Indian Creek Veterinary Hospital, Fort Wayne, Indiana
A Vision for Nationwide Coverage Dr. Mike Korenko shared the company’s vision for making IsoPet® Therapy accessible to pet owners across the country and potentially in select international markets. With the addition of these clinics, the total number of IsoPet® certified regional clinics rises to seven, spanning Washington, Missouri, Maryland, New York, New Hampshire, and Indiana.
Future Expansion Plans Discussions are underway for further expansions, including potential new IsoPet® clinic certifications in Wisconsin, Texas, California, and Washington, reflecting the growing demand for this innovative treatment option.
Raising Awareness in the Veterinary Community Vivos Inc. was set to participate in three recent veterinary conferences, aiming to enhance the veterinary community’s awareness of IsoPet® PRT as a transformative treatment for solid tumors in pets.
The conferences include the Washington State Veterinary Medical Association (WSVMA), Veterinary Cancer Society (VCS), and the American Association of Equine Practitioners (AAEP), promising extensive exposure to the benefits of IsoPet® Therapy.
The certification of three new IsoPet® clinics signifies a major step forward in making advanced cancer treatment more accessible to pets nationwide. Vivos Inc.’s commitment to expanding its network and raising awareness among veterinary professionals highlights the potential of IsoPet® Therapy to change the landscape of pet cancer care.
Looking Ahead: Vivos Inc.’s Vision for the Future
Vivos Inc.’s recent accomplishments are just the beginning. With plans for expanding clinical trials, increasing the IsoPet® clinic network, and participating in major veterinary conferences, Vivos Inc. is poised for further growth and innovation.
In recent strategic financial activities, Form 4 filings have spotlighted notable acquisitions within the company. On October 18, 2023, a transaction was reported involving the acquisition of 100,000 shares at a price of $0.0536 each.
Following closely, another significant filing on November 13, 2023, revealed the purchase of 100,000 shares at a price of $0.0517 per share. These filings collectively underscore a robust investment strategy, reflecting confidence in the company’s direction and future growth potential.
Share Structure Overview (as of March 25, 2024)
Market Cap: $26,480,392
Authorized: 950,000,000
Outstanding: 388,731,533
Restricted: 47,947,725
Unrestricted: 340,783,808
Held at DTC: 334,317,328
Float: 295,921,882 (as of March 8, 2023)
Setting the Strategic Compass
Vivos Inc.’s trajectory over the past year showcases a dynamic and forward-thinking approach to cancer treatment and veterinary care. Underpinned by steadfast leadership, groundbreaking technological advancements, and an expanding network of IsoPet® clinics, the company is actively reshaping the landscape of medical and veterinary oncology. In alignment with these achievements, Vivos Inc. has set forth strategic objectives to further its impact:
- Accelerating Human Clinical Trials: At the forefront of its agenda is to expedite human clinical trials for RadioGel™, capitalizing on the FDA’s Breakthrough Device Program to bring this innovative treatment to the forefront of cancer care swiftly.
- Expanding the IsoPet® Network: A key goal involves widening the reach of the IsoPet® network, not only domestically but also by exploring international market opportunities, thereby extending its revolutionary veterinary care globally.
- Enhancing Professional Awareness: Vivos Inc. is committed to deepening its engagement within the professional veterinary community through targeted conference participation, aiming to elevate awareness and adoption of its pioneering treatments.
These strategic endeavors are meticulously designed to propel Vivos Inc. forward, driving transformative impacts in both medical and veterinary oncology, and underscoring the company’s commitment to excellence and innovation in healthcare.
Vivos Inc. | RadioGel™ | IsoPet® – (OTCMKTS: RDGL)
